Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer
Year: 2019
Type: article
Source: Annals of Oncology
Authors: G. Curigliano, V. Subbiah, J.F. Gainor, D.H. Lee, M.H. Taylor, V. Zhu, R.C. Doebele, G. Lopes, C. Baik, E. Garralda, S.M. Gadgeel, D.-W. Kim, C.D. Turner, M. Palmer, S. Miller
Institutions: European Institute of Oncology, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Asan Medical Center, University of Ulsan, Oregon Health & Science University, OHSU Knight Cancer Institute, University of California, Irvine, University of Colorado Anschutz, University of Miami Health System, Sylvester Comprehensive Cancer Center, Seattle Cancer Care Alliance, University of Washington, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of Michigan, Michigan Medicine, Seoul National University, Seoul National University Hospital, Blueprint Medicines (United States)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Biogen, Spectrum Pharmaceuticals, Celgene, Merck KGaA, Les Laboratories Pierre Fabre, Astex Pharmaceuticals, BeiGene, Institut National de la Santé et de la Recherche Médicale, Astellas Pharma, Institut Gustave-Roussy, Servier, PharmaMar, Ipsen, Symphogen, Genentech, Ignyta, Cilag
OpenAlex ID: W2977881833